|
1
|
Jemal A, Murray T, Ward E, et al: Cancer
statistics. CA Cancer J Clin. 55:10–30. 2005.
|
|
2
|
Tortorelo-Luna G and Mitchell M: The
epidemiology of ovarian cancer. J Cell Bioch. 23:200–207. 1995.
View Article : Google Scholar
|
|
3
|
Gupta D and Lis C: Role of CA125 in
predicting ovarian cancer survival - a review of the
epidemiological literature. J Ovarian Res. 2:132003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lowe K, Shah C, Wallace E, et al: Effects
of personal characteristics on serum CA125, mesothelin and HE4
levels in healthy postmenopausal women at high-risk for ovarian
cancer. Cancer Epidemiol Biomarkers Prev. 17:2480–2487. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chu C and Rubin S: Screening for ovarian
cancer in the general population. Best Pract Res Clin Obstet
Gynaecol. 20:307–320. 2002. View Article : Google Scholar
|
|
6
|
Canevari S, Gariboldi M, Reid J, et al:
Molecular predictors of response and outcome in ovarian cancer.
Crit Rev Oncol Hematol. 60:19–37. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gilks C, Ionescu D, Kalloger S, et al:
Tumor cell type can be reproducibly diagnosed and is of independent
prognostic significance in patients with maximally debulked ovarian
carcinoma. Hum Pathol. 39(8): 1239–1251. 2008. View Article : Google Scholar
|
|
8
|
Pettersson F: Annual report on the results
of treatment in gynecological cancer. Stockholm: International
Federation of Gynecology and Obstetrics; 1994
|
|
9
|
Lu K, Patterson A, Wang L, et al:
Selection of potential markers of epithelial ovarian cancer with
gene expression arrays and recursive descent partition analysis.
Clin Cancer Res. 10:3291–3300. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hoskins W: Prospective on ovarian cancer:
why prevent? Cell Biochem Suppl. 23:189–199. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pettersson F, Kolstad P, Ludwig H, et al:
Annual report on the results of treatment in gynecological cancer.
International Federation of Gynecology and Obstetrics. 1998.
|
|
12
|
Nguyen H, Averette H, Hoskins W, et al:
National survey of ovarian carcinoma VI. Critical assessment of
current International Federation of Gynecology and Obstetrics
staging system. Cancer. 72:3007–3011. 1993. View Article : Google Scholar
|
|
13
|
Bast RC Jr, Brewer M, Zou C, et al:
Ovarian cancer prevention and early detection: mission impossible?
Recent Results Cancer Res. 174:91–900. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang Z, Yu Y, Xu F, et al: Combining
multiple serum tumor markers improves detection of stage I
epithelial ovarian cancer. Gynecol Oncol. 107:526–531. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Havrilesky L, Whitehead C, Rubatt J, et
al: Evaluation of biomarker panels for early stage ovarian cancer
detection and monitoring for disease recurrence. Gynecol Oncol.
110:374–382. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Scholler N, Crawford M, Sato A, et al:
Bead-based ELISA assays for validation of ovarian cancer early
detection markers. Clin Cancer Res. 1:2117–2124. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nosov V, Feng S, Malaika A, et al:
Validation of serum biomarkers for detection of early-stage ovarian
cancer. Am J Obstet Gynecol. 200:639 e1–5. 2009.PubMed/NCBI
|
|
18
|
Oikonomopolou K, Li L, Zheng Y, et al:
Prediction of ovarian cancer prognosis and response to chemotherapy
by a serum-based multiparametric biomarker panel. Br J Cancer.
99:1103–1113. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pauler D, Menon U, McIntosh M, et al:
Factors influencing serum Ca125II levels in healthy postmenopausal
women. Cancer Epidemiol Biomarkers Prev. 10:489–493.
2001.PubMed/NCBI
|
|
20
|
Bast R and Knapp R: Use of CA125 antigen
in diagnosis and monitoring of ovarian carcinoma. Eur Obset Gyncol
Reprod Biol. 19:354–356. 1995. View Article : Google Scholar
|
|
21
|
Fishman D: The present and future of
biomarkers for the early detection of epithelial ovarian carcinoma.
CME J Gynecol Oncol. 4:33–36. 1999.
|
|
22
|
Jacobs I and Bast R: The Ca125
tumor-associated antigen: a review of literature. Human Reprod.
4:1–12. 1989.
|
|
23
|
Wollas R, Xu F, Jacobs I, et al: Elevation
of multiple serum markers in patients with stage I ovarian cancer.
JNCI. 85:1748–1751. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bast R: Status of tumor markers in ovarian
cancer screening. J Clin Oncol. 21:200–205. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Skates S, Xu F, Yu H, et al: Toward an
optimal algorithm for ovarian cancer screening with longitudinal
tumor markers. Cancer. 76:2004–2010. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shah C, Lowe K, Paley P, et al: Influence
of ovarian cancer risk status on the diagnostic performance of the
serum biomarkers mesothelin, HE4 and CA125. Cancer Epidemiol
Biomarkers Prev. 18:1365–1372. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jacobs I and Menon U: Progress and
challenges in screening for early detection of ovarian cancer. Mol
Cell Proteomics. 3:355–366. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Palmer C, Duan X, Hawley S, et al:
Systematic evaluation of candidate blood markers for detecting
ovarian cancer. PLoS One. 3:e26332008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chang K and Pastan I: Molecular cloning of
mesothelin, a differentiation antigen present on mesothelium,
mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA.
93:136–140. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chang K, Pai LH, Batra JK, et al:
Characterization of the antigen (CAK1) recognized by monoclonal
antibody K1 present on ovarian cancers and normal mesothelium.
Cancer Res. 52:181–186. 1992.PubMed/NCBI
|
|
31
|
Blaustein A: Peritoneal mesothelium and
ovarian surface cells-shared characteristics. Int J Gynecol Pathol.
3:361–375. 1984.PubMed/NCBI
|
|
32
|
Okamura H, Katabuchi H, Nitta M, et al:
Structural changes and cell properties of human ovarian surface
epithelium in ovarian pathophysiology. Microsc Res Tech.
69:469–481. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dubeau L: The cell of origin of ovarian
epithelial tumours. Lancet Oncol. 9:1191–1197. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Okamura H: Detailed morphology of human
ovarian surface epithelium focusing on its metaplastic and
neoplastic capability. Ital J Anat Embryol. 106(Suppl 2): 263–276.
2001.PubMed/NCBI
|
|
35
|
Kurman RJ and Shih IM: Pathogenesis of
ovarian cancer: lessons from morphology and molecular biology and
their clinical implications. Int J Gynecol Pathol. 27:151–160.
2008.PubMed/NCBI
|
|
36
|
McIntosh M, Drescher C, Karlan B, et al:
Combining CA125 and SMRP serum markers for diagnosis and early
detection of ovarian carcinoma. Gynecol Oncol. 95:9–15. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Scholler N, Garvik B, Hayden-Ledbetter M,
Kline T and Urban N: Development of a CA125-mesothelin cell
adhesion assay as a screening tool for biologics discovery. Cancer
Lett. 247:130–136. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Drapkin R, Von Horsten H, Lin Y, et al:
Human epididymis protein 4 (HE4) is a secreted glycoprotein that is
overexpressed by serous and endometrioid ovarian carcinomas. Cancer
Res. 65:2162–2169. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Galgano M, Hampton G and Frierson H:
Comprehensive analysis of HE4 expression in normal and malignant
human tissues. Mod Pathol. 19:847–853. 2006.PubMed/NCBI
|
|
40
|
Hellström I, Raycraft J, Hayden-Ledbetter
M, et al: The HE4 (WFDC2) protein is a biomarker for ovarian
carcinoma. Cancer Res. 63:3695–3700. 2003.PubMed/NCBI
|
|
41
|
Moore R, Brown A, Miller C, et al: Utility
of a novel serum tumor biomarker HE4 in patients with uterine
cancer. J Clin Oncol. 24:18S2006.
|
|
42
|
Berry N, Cho Y, Harrington M, et al:
Transcriptional targeting in ovarian cancer cells using the human
epididymis protein 4 promoter. Gynecol Oncol. 92:896–904. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Moore R, Brown A, Miller M, et al: The use
of multiple novel tumor biomarkers for the detection of ovarian
carcinoma in patients with a pelvic mass. Gynecol Oncol.
108:402–408. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Moore R, McMeekin D, Brown A, et al: A
novel multiple marker bioassay utilizing HE4 and CA125 for the
prediction of ovarian cancer in patients with a pelvic mass.
Gynecol Oncol. 112:40–46. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pauler D, Menon U, McIntosh M, et al:
Factors influencing serum CA125II levels in healthy postmenopausal
woman at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers
Prev. 17:2480–2487. 2008. View Article : Google Scholar
|
|
46
|
Hellström I, Raycraft J, Kanan S, et al:
Mesothelin variant I is released from tumor cells as a diagnostic
marker. Cancer Epidemiol Biomarker Prev. 15:1014–1020.
2006.PubMed/NCBI
|
|
47
|
Das P and Bast R Jr: Early detection of
ovarian cancer. Biomark Med. 2:291–303. 2008. View Article : Google Scholar
|
|
48
|
Köbel M, Kalloger S, Boyd N, et al:
Ovarian carcinoma subtypes are different diseases: implication for
biomarker studies. PLoS Med. 5:e2322008.PubMed/NCBI
|
|
49
|
Kozak K, Su F, Whitelegge J, et al:
Characterization of serum biomarkers for detection of early stage
ovarian cancer. Proteomics. 5:4589–4596. 2005. View Article : Google Scholar : PubMed/NCBI
|
